Latest news with #CEAP
GMA Network
10-07-2025
- Politics
- GMA Network
Catholic schools favor reform over repealing SHS program
Catholic schools in the country have opposed the proposal to remove senior high school (SHS) from the K to 12 program, calling the move 'untimely' and 'dangerously shortsighted.' In a statement, the Catholic Educational Association of the Philippines (CEAP) and the CBCP Episcopal Commission on Catholic Education (ECCE) said in a joint statement the proposed measure threatens the 'vision rooted in equity, global parity, and holistic learner development.' "Reform, not repeal, is the only rational and just way forward,' the groups said. 'Flaws in execution should not be mistaken for flaws in the framework,' the groups added. The CEAP and ECCE proposed that instead of abolishing the program, the government should expand and strengthen the SHS Voucher Program so that more learners could enroll in senior high school. To address the graduates' employment readiness, CEAP said curriculum tracks should be aligned to market demands by strengthening partnerships between schools and the industry. The regional centers of excellence should also guide struggling schools by upskilling SHS teachers and reforming a job-relevant curriculum. 'Rather than breaking what is still being built, the government should commit to a full review of SHS implementation and institute reforms where necessary without sacrificing its gains,' CEAP said. 'Reverting to a 10-year cycle would dismantle existing structures, waste public and private investment, and once again send Filipino students into college or the workforce underprepared,' it added. Senate President Pro Tempore Jinggoy Estrada has filed a measure seeking to rationalize the basic education system by removing the SHS, as it 'still has not fully achieved its goal' to produce skilled and job-ready graduates 12 years after the Enhanced Basic Education Act of 2013 was enacted into law. Education Secretary Sonny Angara earlier acknowledged the lapses in the implementation of SHS but said it is up to the Congress to continue to abolish the program. 'Hindi maganda ang naging implementation nitong nakaraang dekada. Masyadong marami ang subjects at nakahon masyado ang mga bata. Hindi sila nakakapili ng subject/s,' Angara said in a statement. (The SHS' implementation in the last decade has not been good. There were too many subjects and the learners were constrained. They were not able to choose subject/s.) — BAP, GMA Integrated News
Euronews
28-05-2025
- Business
- Euronews
Circular Economy Act: what are the European Commission's tools to get the economics right?
'We have a lot of policy already, what we need is to get the economics right', European Commissioner for the Environment Jessika Roswall told Euronews. Roswall is the architect of the EU Commission's future Circular Economy Act, which is to succeed the Circular Economy Action Plan (CEAP) adopted five years ago. The initiative should include updating existing rules to foster 'circular competitiveness' and boost the EU's recycling rate. In 2022, only 12% of products consumed came from recycling. The plan could include a revision of the WEEE (Waste from Electrical and Electronic Equipment) Directive, which governs the rules and targets for the collection and treatment of e-waste, from small batteries to photovoltaic panels. In almost 20 years, the WEEE Directive has led to a tenfold increase in the amount of e-waste recovered and properly treated in the EU, but not all member states have achieved the targets set. Quantities of WEEE are still not collected, improperly treated or illegally exported. The EU wants to increase the proportion of recovered materials in order to reduce the proportion of virgin materials imported for new electrical and electronic equipment. The Circular Economy Act should focus on the recovery of critical raw materials. This strategy is presented as a means of strengthening the EU's economic security against a backdrop of international trade tensions. 'The circularity numbers are too low. This geopolitical situation must be the time when we actually go circular', Commissoner Roswall told Euronews. In 2024, the EU adopted the Critical Raw Materials Act (CRM Act), which is intended to strengthen the EU's security of supply of a series of metals and other components essential to the green and digital transitions. The European Union has drawn up a regularly updated list of materials considered 'critical', such as rare-earth metals, copper or cobalt, and another of materials considered 'strategic', such as bismuth and magnesium metal. The EU's objective is to achieve a recycling rate of 25% of CRMs, compared with around 1% today. This requires investment in the necessary infrastructure as part of the Clean Industrial Deal presented last year. The circular economy should also apply to other sectors of the economy, such as construction, textiles and the automotive industry. The Act in preparation is set to provide for the revision of the Waste Framework Directive and promote the creation of a 'common market for waste'. Despite efforts at harmonisation, the existing fragmentation between national requirements, as in the case of Extended Producer Responsibility (EPR) systems, raises problems of competition and costs. An intra-EU waste market is wanted by Brussels, which conversely recently tightened the rules against the export of waste outside the EU. 'We need to change our mindset and see waste as an asset', Roswall added, specifying that she also considered water as waste. The EU recently strengthened its legislation on urban wastewater. It plans to maximise the reuse of water for irrigation in the continent's largest treatment stations. Alongside recycling, the EU is also encouraging the extension of product lifetimes. The Ecodesign for Sustainable Products Regulation (ESPR) entered into force in 2024, and is aimed at creating economic opportunities in remanufacturing, recycling or repair. The European Commission has put forward the concept of a 'right to repair', in the form of incentives to make repairing products easier and more attractive, in order to reduce waste. A directive aimed at 'Empowering consumers for the green transition' was also adopted to offer consumers better information on the products durability. According to a 2020 survey, 77% of Europeans said they would rather repair their goods, but had to buy new ones because of the lack of repair services.
Miami Herald
13-05-2025
- Health
- Miami Herald
Three-Year VenoValve(R) First-in-Human Trial Data Published in the Annals of Vascular Surgery
IRVINE, CA / ACCESS Newswire / May 13, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that its manuscript titled, "Three-Year Outcomes of Surgical Implantation of a Novel Bioprosthetic Valve for the Treatment of Deep Venous Reflux1," has been published in the in the peer-reviewed journal, Annals of Vascular Surgery. The VenoValve was surgically implanted in the femoral vein of eleven subjects with active or healed venous ulcers (CEAP classifications C5-C6). Eight subjects completed three years of follow-up, with key findings including: The VenoValve remained safe and effective, achieving target patency and maintaining competence and clinical benefits The VenoValve is a potential first-in-class, surgical replacement venous valve for patients with severe deep venous CVI. The Company estimates that there are approximately 2.5 million potential new patients each year in the U.S. that could be candidates for the VenoValve. The Company has submitted a pre-market authorization (PMA) application for the VenoValve to the U.S. Food and Drug Administration (FDA), with a decision anticipated in the second half of 2025. About CVI Severe, deep venous Chronic Venous Insufficiency (CVI) is a debilitating disease that is most often caused by blood clots (deep vein thromboses or DVTs) in the deep veins of the leg. When valves inside of the veins of the leg fail, blood flows in the wrong direction and pools in the lower leg, causing pressure within the veins of the leg to increase (venous hypertension). Symptoms of severe CVI include leg swelling, pain, edema, and in the most severe cases, recurrent open sores known as venous ulcers. The disease can severely impact everyday functions such as sleeping, bathing, dressing, and walking, and is known to result in high rates of depression and anxiety. There are currently no effective treatments for severe CVI of the deep vein system caused by valvular incompetence. Estimates indicate that CVI costs the U.S. healthcare system in excess of $4 billion each year. About enVVeno Medical Corporation enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease. The Company's lead product, the VenoValve®, is a first-in-class surgical replacement venous valve being developed for the treatment of deep venous Chronic Venous Insufficiency (CVI). The Company is also developing a non-surgical, transcatheter based replacement venous valve for the treatment of deep venous CVI called enVVe®. CVI occurs when valves inside of the veins of the leg become damaged, resulting in the backwards flow of blood (reflux), blood pooling in the lower leg, increased pressure in the veins of the leg (venous hypertension) and in severe cases, venous ulcers that are difficult to heal and become chronic. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the leg, and back to the heart and lungs. The VenoValve is currently being evaluated in the SAVVE U.S. pivotal study and the Company is currently performing the final testing necessary to seek approval for the pivotal trial for enVVe. Cautionary Note on Forward-Looking Statements This press release and any statements of stockholders, directors, employees, representatives and partners of enVVeno Medical Corporation (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results and timing (may differ significantly from those set forth or implied in the forward-looking statements. Forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law. INVESTOR CONTACT:Jenene Thomas, JTC Team, LLC NVNO@ 824-0775 MEDIA CONTACT:Glenn Silver, FINN Partners 818-8198 SOURCE: enVVeno Medical Corporation
Associated Press
13-05-2025
- Health
- Associated Press
Three-Year VenoValve(R) First-in-Human Trial Data Published in the Annals of Vascular Surgery
Promising results from the first-in-human study demonstrated that, at three-years post implantation, VenoValve remained safe and effective--achieving a high rate of patency, restoring deep venous competence and maintaining clinical benefitsCompany has submitted PMA application for the VenoValve to the U.S. Food and Drug Administration (FDA) with a decision anticipated in the second half of 2025 IRVINE, CA / ACCESS Newswire / May 13, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ('enVVeno' or the 'Company'), a company setting new standards of care for the treatment of deep venous disease, today announced that its manuscript titled, " Three-Year Outcomes of Surgical Implantation of a Novel Bioprosthetic Valve for the Treatment of Deep Venous Reflux 1,' has been published in the in the peer-reviewed journal, Annals of Vascular Surgery. The VenoValve was surgically implanted in the femoral vein of eleven subjects with active or healed venous ulcers (CEAP classifications C5-C6). Eight subjects completed three years of follow-up, with key findings including: The VenoValve is a potential first-in-class, surgical replacement venous valve for patients with severe deep venous CVI. The Company estimates that there are approximately 2.5 million potential new patients each year in the U.S. that could be candidates for the VenoValve. The Company has submitted a pre-market authorization (PMA) application for the VenoValve to the U.S. Food and Drug Administration (FDA), with a decision anticipated in the second half of 2025. About CVI Severe, deep venous Chronic Venous Insufficiency (CVI) is a debilitating disease that is most often caused by blood clots (deep vein thromboses or DVTs) in the deep veins of the leg. When valves inside of the veins of the leg fail, blood flows in the wrong direction and pools in the lower leg, causing pressure within the veins of the leg to increase (venous hypertension). Symptoms of severe CVI include leg swelling, pain, edema, and in the most severe cases, recurrent open sores known as venous ulcers. The disease can severely impact everyday functions such as sleeping, bathing, dressing, and walking, and is known to result in high rates of depression and anxiety. There are currently no effective treatments for severe CVI of the deep vein system caused by valvular incompetence. Estimates indicate that CVI costs the U.S. healthcare system in excess of $4 billion each year. About enVVeno Medical Corporation enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease. The Company's lead product, the VenoValve®, is a first-in-class surgical replacement venous valve being developed for the treatment of deep venous Chronic Venous Insufficiency (CVI). The Company is also developing a non-surgical, transcatheter based replacement venous valve for the treatment of deep venous CVI called enVVe®. CVI occurs when valves inside of the veins of the leg become damaged, resulting in the backwards flow of blood (reflux), blood pooling in the lower leg, increased pressure in the veins of the leg (venous hypertension) and in severe cases, venous ulcers that are difficult to heal and become chronic. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the leg, and back to the heart and lungs. The VenoValve is currently being evaluated in the SAVVE U.S. pivotal study and the Company is currently performing the final testing necessary to seek approval for the pivotal trial for enVVe. Cautionary Note on Forward-Looking Statements This press release and any statements of stockholders, directors, employees, representatives and partners of enVVeno Medical Corporation (the 'Company') related thereto contain, or may contain, among other things, certain 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as 'projects,' 'may,' 'will,' 'could,' 'would,' 'should,' 'believes,' 'expects,' 'anticipates,' 'estimates,' 'intends,' 'plans,' 'potential' or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results and timing (may differ significantly from those set forth or implied in the forward-looking statements. Forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law. INVESTOR CONTACT: Jenene Thomas, JTC Team, LLC [email protected] (908) 824-0775 MEDIA CONTACT: Glenn Silver, FINN Partners [email protected] (973) 818-8198 SOURCE: enVVeno Medical Corporation press release
Yahoo
13-05-2025
- Business
- Yahoo
Three-Year VenoValve(R) First-in-Human Trial Data Published in the Annals of Vascular Surgery
Promising results from the first-in-human study demonstrated that, at three-years post implantation, VenoValve remained safe and effective--achieving a high rate of patency, restoring deep venous competence and maintaining clinical benefits Company has submitted PMA application for the VenoValve to the U.S. Food and Drug Administration (FDA) with a decision anticipated in the second half of 2025 IRVINE, CA / / May 13, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that its manuscript titled, "Three-Year Outcomes of Surgical Implantation of a Novel Bioprosthetic Valve for the Treatment of Deep Venous Reflux1," has been published in the in the peer-reviewed journal, Annals of Vascular Surgery. The VenoValve was surgically implanted in the femoral vein of eleven subjects with active or healed venous ulcers (CEAP classifications C5-C6). Eight subjects completed three years of follow-up, with key findings including: Primary patency: 79% (Kaplan-Meier curve) at three years Symptom relief: 7 point improvement Venous Clinical Severity Score; 84% reduction in pain on the Visual Analog Scale (VAS) The VenoValve remained safe and effective, achieving target patency and maintaining competence and clinical benefits The VenoValve is a potential first-in-class, surgical replacement venous valve for patients with severe deep venous CVI. The Company estimates that there are approximately 2.5 million potential new patients each year in the U.S. that could be candidates for the VenoValve. The Company has submitted a pre-market authorization (PMA) application for the VenoValve to the U.S. Food and Drug Administration (FDA), with a decision anticipated in the second half of 2025. About CVI Severe, deep venous Chronic Venous Insufficiency (CVI) is a debilitating disease that is most often caused by blood clots (deep vein thromboses or DVTs) in the deep veins of the leg. When valves inside of the veins of the leg fail, blood flows in the wrong direction and pools in the lower leg, causing pressure within the veins of the leg to increase (venous hypertension). Symptoms of severe CVI include leg swelling, pain, edema, and in the most severe cases, recurrent open sores known as venous ulcers. The disease can severely impact everyday functions such as sleeping, bathing, dressing, and walking, and is known to result in high rates of depression and anxiety. There are currently no effective treatments for severe CVI of the deep vein system caused by valvular incompetence. Estimates indicate that CVI costs the U.S. healthcare system in excess of $4 billion each year. About enVVeno Medical Corporation enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease. The Company's lead product, the VenoValve®, is a first-in-class surgical replacement venous valve being developed for the treatment of deep venous Chronic Venous Insufficiency (CVI). The Company is also developing a non-surgical, transcatheter based replacement venous valve for the treatment of deep venous CVI called enVVe®. CVI occurs when valves inside of the veins of the leg become damaged, resulting in the backwards flow of blood (reflux), blood pooling in the lower leg, increased pressure in the veins of the leg (venous hypertension) and in severe cases, venous ulcers that are difficult to heal and become chronic. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the leg, and back to the heart and lungs. The VenoValve is currently being evaluated in the SAVVE U.S. pivotal study and the Company is currently performing the final testing necessary to seek approval for the pivotal trial for enVVe. Cautionary Note on Forward-Looking Statements This press release and any statements of stockholders, directors, employees, representatives and partners of enVVeno Medical Corporation (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results and timing (may differ significantly from those set forth or implied in the forward-looking statements. Forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law. INVESTOR CONTACT:Jenene Thomas, JTC Team, LLC NVNO@ 824-0775 MEDIA CONTACT:Glenn Silver, FINN Partners 818-8198 SOURCE: enVVeno Medical Corporation View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
